Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant CapOx in Intermediate Risk Rectal Cancer
NCT04103697Phase 3Unknown
- Sponsor
- N.N. Blokhin Russian Cancer Research Center
- Start
- Aug 2019
- Primary completion
- Aug 2024
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine, oxaliplatin in rectal cancer, sponsored by N.N. Blokhin Russian Cancer Research Center. Status: unknown.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04103697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04103697.